$1,162.23
▼ -0.1% Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 21
▼ 1
Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?
Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads
Top Research Reports for Eli Lilly, Costco & Morgan Stanley
Overview
52-week range
$624
$1.2K
99% of range
Avg surprise (last 2)
+3.7%
Avg reaction (last 1)
-11.7%
0% positive
Latest IV / EM
37%
EM ±2.2% · $1165 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $8.26 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $6.21 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $6.31 | $5.61 | +12.5% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $3.34 | $3.52 | -5.1% | — | -11.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.07 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $3.28 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $2.48 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.06 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.95 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | BMO | $7.47 | $6.31 | +18.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.80B | — | $17.60B | $15.56B | $12.73B | — | $11.44B | $11.30B |
| Cost of revenue | $3.58B | — | $3.01B | $2.45B | $2.23B | — | $2.17B | $2.17B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $7.40B | — | $5.58B | $5.66B | $2.76B | — | $970M | $2.97B |
| EPS (diluted) | $8.26 | — | $6.21 | $6.29 | $3.06 | — | $1.07 | $3.28 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B |
| Inventory | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B | $6.48B |
| Total current assets | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B | $30.20B |
| Total assets | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.71B | $75.61B | $71.87B |
| Long-term debt | $39.37B | $40.87B | $40.87B | $34.18B | $34.50B | $28.53B | $29.05B | $23.73B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.19B | $14.24B | $13.56B |